AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02688426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 6J Low-Level Laser Therapy (6J LLLT)
Description: irradiation will be perform with 6J
Study NCT03832036 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Paraspinal Mapping and Quantitative Sensory Pain Test
Description: Participants will be tested at baseline.
Study NCT02163486 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group U (UNIQUE)
Description: Before LMA-Unique was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LMA-Unique cuff.
Study NCT02163486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-GEL
Description: Before I-gel was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the I-GEL cuff.~I-GEL: K-Y Jelly® is a registered trademark of Johnson and Johnson Inc
Study NCT02618408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-810 (18 mg)
Description: Subjects were randomized to receive SPN-810 low dose (18 mg) twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
Study NCT02618408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-810 (36 mg)
Description: Subjects were randomized to receive SPN-810 high dose (36 mg) twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
Study NCT02618408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects were randomized to receive Placebo twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
Study NCT00218166 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: GABA Agonists
Description: GABA drugs administered acutely by mouth
Study NCT00662948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2 every 8 weeks during 24 months
Study NCT00662948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibritumomab tiuxetan
Description: One dose of 90Y Ibritumomab tiuxetan, 0,4 mCi/Kg
Study NCT00160641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: Strength and Form: 1 ml of Liquid product containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.~Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks.~Duration: Until end of study.
Study NCT03715075 — intervention group
Intervention type: PROCEDURE
Intervention: Caesarean Section
Description: Caesarean Section
Study NCT03915730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Initial periodontal therapy
Description: Scaling and root planing and polishing with specific curettes were performed to patients with CP and oral hygiene education was provided to each patient.
Study NCT03812705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fecal microbiome transplantation
Description: 1. Stop antibiotics treatment 1 day before fecal microbiome transplantation;~2. Fasting food 6 hours before fecal microbiome transplantation;~3. Give Ondansetron intravenously 1 hour before fecal microbiome transplantation for vomiting prevention;~4. Perform fecal microbiome transplantation under colonoscopy or gastroscopy;~5. Perform up to 4 times if patient response;~6. Stop if no response after twice fecal microbiome transplantation.
Study NCT04346420 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard interface
Description: The standard interface for administering oxygen (nasal cannula or oxygen mask) is worn by the patient. Oxygen output is adapted to reach a SpO2 target of 94%.
Study NCT04346420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double-Trunk Mask
Description: The standard nasal cannula interface accompanied with the DTM is worn by the patient. Oxygen output is adapted to reach a SpO2 target of 94%.
Study NCT00698893 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes simplex candidate (gD) vaccine GSK208141
Description: Intramuscular injection, 2 doses, 2 different formulations (with and without MPL)
Study NCT05284461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dental implant with transepithelial abutments manufactured by Galimplant Dental System (Spain)
Description: Dental implants with transepithelial abutments with distinct morphology
Study NCT05284461 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: dental implant with transepithelial abutments manufactured by Galimplant Dental System (Spain)
Description: Dental implants with transepithelial abutments with distinct morphology
Study NCT01390285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electric nerve stimulation
Description: The subjects that enter the TENS-group will be asked to apply the TENS therapy for at least 40 minutes continuously per day. The parameters of the current will not be changed during the study (pulse: 250 µsec; internal frequency: 100Hz; burst frequency 3 Hz; intensity: until an unpleasant but not painful sensation is acquired).
Study NCT01390285 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcutaneous electrical nerve stimulation
Description: The patients that are assigned to the sham TENS will receive an inactive placebo TENS therapy using a nonfunctional unit that appears to work but provides no stimulus.
Study NCT01561430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2886721
Study NCT01561430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03142906 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Scan
Description: The preoperative point of care ultrasound includes a protocolized focused cardiac ultrasound, lung and pleural ultrasound and a gastric volume and content ultrasound assessment, all of which will be performed as an adjunct to the anesthesiologist's assessment. The result of this ultrasound examination will be disclosed to the anesthesiologist and patient care teams. Repeat ultrasounds may be done as the patient's clinical condition changes, or as requested by the anesthesiologist or patient care team.
Study NCT02034058 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Wingspan Stent System
Description: The Wingspan Stent System is used with the Gateway PTA Balloon Catheter. The Wingspan Stent System is a self-expanding, Nitinol stent and delivery system intended for use in the treatment of intracranial atherosclerotic disease. The Gateway PTA Balloon Catheter is an over-the-wire balloon catheter intended for the pre-dilation of the lesion prior to insertion and deployment of the Wingspan Stent System.
Study NCT04813302 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap and connective tissue graft
Description: CAF+CTG treatment will be performed by starting with two vertical releasing incisions lateral to the teeth to be treated and split-full-split thickness flap will be raised beyond the MGJ. The periosteum will be cut, and a blunt dissection into the vestibular lining mucosa will be carried out to eliminate muscle tension so that the mucosal flap can be passively positioned above the level of CEJ on the tooth. The papillae adjacent to the involved teeth will be de-epithelialized. CTG of 1mm in thickness will be harvested from the posterior palate by means of disepithelization of a free gingival graft, cut to the exact size of the defect, and placed over the dehisced defect, sutured to the interdental papillae and subsequently covered with CAF. Sling sutures will be placed to stabilize the flap in a coronal position about 1-2 mm above the CEJ , followed by interrupted sutures to close the releasing incisions.
Study NCT03808428 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Group
Description: Provide sensory feedback to help subjects relearn how to walk in correct gait pattern.
Study NCT04451291 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Decidual Stromal Cells (DSC)
Description: DSCs are involved in the immune system during pregnancy. The DSCs used in this study will come from laboratory grown allogeneic human decidual stromal cells obtained from donated placentas.
Study NCT00979719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Description: patients will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
Study NCT00979719 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Active Control Group (ACG)
Description: Patients in the ACG will get an interactive computerized standard program which has been proven to be effective (Göhner, W. \& Fuchs, R. (2007). Änderung des Gesundheitsverhaltens. MoVo-Gruppenprogramme für körperliche Aktivität und gesunde Ernährung. Göttingen: Hogrefe.)
Study NCT01668381 — intervention group
Intervention type: PROCEDURE
Intervention: radiofrequency ablation
Description: the patients are prepared by local anesthesia and intravenous sedative.guided by the ultrasound,the antenna used for radiofrequency ablation ablation is placed in the tumor to destroy tumor tissues,the output power and duration are depended by the tumor volume and location.
Study NCT03114423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMDR-Therapy
Description: The EMDR-protocol from Hase (2008) was used
Study NCT03114423 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: For the training the COGPACK-program from Marker (2008) was used
Study NCT01917708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: All patients will receive 4 doses of abatacept in addition to standard GVHD prophylaxis with cyclosporine and mycophenolate mofetil.
Study NCT00293241 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Managed Ventricular Pacing programmed ON/OFF
Description: Device programming
Study NCT00703170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Study NCT00703170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Study NCT04200092 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 0.5mg AZ-010
Description: Subject will receive a single inhaled dose (0.5mg) of AZ-010 or matching Staccato Placebo
Study NCT04200092 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 1mg AZ-010
Description: Subject will receive a single inhaled dose (1.0 mg) of AZ-010 or matching Staccato Placebo
Study NCT02527941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Participants will be provided with oral metronidazole 400mg po tid for one week, and followed up one month after treatment initiation.
Study NCT03437213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia group
Description: Induction of general anesthesia with fentanyl, (1mcg / kg), propofol (1-2 mg / kg), atracurium (0.5 mg / kg), intubation. Anesthesia maintained using Propofol (4-6) mg/kg/h, fentanyl (0.5-1) μg/kg/h. to be modified according to analgesic needs and hemodynamics. 10mg atracurium when the 2nd twitch of train of four appears.
Study NCT03437213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Total intravenous plus block group
Description: Ultrasound guidance identifies the paravertebral space using a linear high-frequency (10-12 MHz) probe in the transverse plane in the midline, rotate the probe to the longitudinal plane, and scan in a medial-to-lateral direction. Locate the desired segment shift from the cephalad aspect of the sacrum. The transverse scan will show a hyperechoic outline of the vertebral spinous and transverse processes. Use the loss of resistance technique. Bilaterally inject (5ml) bupivacaine 0.5% for each segment. Induction of anesthesia after 30 minutes with fentanyl, (1mcg / kg), propofol (1-2 mg / kg), atracurium (0.5 mg / kg),then prone position.
Study NCT04200092 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 3mg AZ-010
Description: Subject will receive a single inhaled dose (3.0 mg) of AZ-010 or matching Staccato Placebo
Study NCT03682380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant High Dose
Description: In Part 1, Part 2, and Part 3 (3A and 3C), Seltorexant high dose (either a high dose tablet or two low dose tablets) will be administered orally.
Study NCT03682380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant Low Dose
Description: In Part 3 (3B and 3C), Seltorexant low dose will be administered orally.
Study NCT02863705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brimonidine tartrate/timolol malate Ophthalmic Solution
Description: One drop of brimonidine tartrate/timolol malate (COMBIGAN®) Ophthalmic Solution in the affected eye, administered twice daily for 12 months
Study NCT02863705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost ophthalmic solution 0.01%
Description: Bimatoprost ophthalmic solution 0.01% (LUMIGAN®) administered once daily in the evening 5 minutes after COMBIGAN® instillation if additional lowering IOP is needed
Study NCT01972854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: riboflavin solution
Description: 0.12% riboflavin ophthalmic solution
Study NCT04200092 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AZ-010 1mg
Description: 2-period, 2-treatment open-label crossover design
Study NCT04200092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Granisetron 1mg
Description: 2-period, 2-treatment open-label crossover design
Study NCT01530529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05180999
Description: Single dose of 30 mg of PF-05180999 administered to fasted subjects as an immediate-release powder-in-capsule formulation
Study NCT01530529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05180999
Description: Single dose of 30 mg of PF-05180999 administered to fasted subjects as a modified-release formulation
Study NCT01530529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05180999
Description: Single dose of 120 mg of PF-05180999 administered to fasted subjects as a modified-release formulation
Study NCT01530529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05180999
Description: Single dose of 30 mg of PF-05180999 administered to fed subjects as a modified-release formulation
Study NCT03288454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciraparantag
Description: Ciraparantag (administered over 10 minutes)
Study NCT01972854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo solution
Description: 0.0% riboflavin ophthalmic solution
Study NCT03288454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline for injection
Study NCT01972854 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: KXL System
Description: 30mW/cm2
Study NCT01972854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KXL System
Description: 30mW/cm2
Study NCT00848445 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Guidant Pulsar Max II or Insignia Plus DR
Description: market approved pacemaker. programmed per protocol
Study NCT00848445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guidant Pulsar Max II or Insignia Plus DR
Description: market approved pacemaker. programmed per protocol
Study NCT00848445 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial pacing preference turned on or off
Description: programing changes in the device
Study NCT00848445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atrial pacing preference turned on or off
Description: programing changes in the device
Study NCT00345501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: Iloprost 1ng/kg/min IV starting 1 hour before the procedure and continuing for 4 hours after its end
Study NCT00345501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV (Normal saline) starting 1 hour before the procedure and continuing for 4 hours after its end
Study NCT02759861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: harvoni
Description: 8 or 12 weeks of harvoni therapy with monthly nursing visiting to monitor alcohol and adherence of harvoni therapy
Study NCT03999112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metacognitive Reflection and Insight Therapy (MERIT)
Description: A psychological therapy aiming to increase the ability of individuals to synthesise perceptions about themselves and others; to then form complex narratives which recognise the occurrence of these within particular social contexts; and to use these to form responses to psychological problems.
Study NCT00367029 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individualized Print-Based Motivational Program
Description: Study researchers will develop individualized reports, manuals, and tip sheets that include feedback and strategies for increasing physical activity for each participant. Materials will be mailed to participants 14 times throughout the year.~Participants in the enhanced intervention will receive additional materials that focus on increasing social support, self regulation, and outcome expectations, as well as materials on how to effectively monitor physical activity levels. They will also attend one study visit to assess their goals with the research staff.
Study NCT00367029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Print-Based Motivational Program
Description: Study researchers will develop individualized reports, manuals, and tip sheets that include feedback and strategies for increasing physical activity for each participant. Materials will be mailed to participants 14 times throughout the year.~Participants in the enhanced intervention will receive additional materials that focus on increasing social support, self regulation, and outcome expectations, as well as materials on how to effectively monitor physical activity levels. They will also attend one study visit to assess their goals with the research staff.
Study NCT00331955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00331955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT00331955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00331955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03634917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acamprosate Calcium
Description: 1 capsule with 666 mg Acamprosate
Study NCT03634917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Description: 1 capsule with 1500 mg Calcium Carbonate
Study NCT03634917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 Capsule with Placebo (lactose monohydrate, micro crystalline cellulose, magnesium stearate)
Study NCT03634917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo lead in
Description: 1 Capsule with Placebo (lactose monohydrate, micro crystalline cellulose, magnesium stearate)
Study NCT03634917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lead in
Description: 1 Capsule with Placebo (lactose monohydrate, micro crystalline cellulose, magnesium stearate)
Study NCT01262599 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham PEMF Device
Description: Inactive device placed in the same manner as the active device; does not deliver pulsed electromagnetic fields
Study NCT01262599 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ivivi Torino II PEMF Device
Description: The PEMF device to be employed in this study is FDA cleared for adjunctive use in the palliative treatment of postoperative pain and edema in superficial soft tissue (510(k) number: K903675). The PEMF device will be taped over the affected breast and abdomen. The PEMF signal will consist of a 2 msec burst of 27.12 MHz sinusoidal waves repeating at 2 bursts/sec. The device will automatically provide a 15 minute treatment every 2 hours. Supplied by Ivivi Health Sciences, LLC.
Study NCT00861380 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: 2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination
Study NCT00861380 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)
Description: 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination.~Control 3+1 and Control 2+1 groups, only for children \< 12 months of age at the time of first study vaccination.
Study NCT00861380 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)
Description: 2 Intramuscular injections. Control 3+1 and Control 2+1 groups, only for children >= 12 months of age at the time of first study vaccination.